These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 32627420)

  • 21. A randomized, double-blind, single-dose, three-arm, parallel group study to determine pharmacokinetic similarity of ABP 959 and eculizumab (Soliris
    Chow V; Pan J; Chien D; Mytych DT; Hanes V
    Eur J Haematol; 2020 Jul; 105(1):66-74. PubMed ID: 32196749
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX02 to reference CN- and EU-sourced trastuzumab in healthy subjects.
    Zhu X; Ding Y; Yu Y; Wang M; Zhou W; Wang J; Zhu X; Zhang H; Wang M; Chai K; Zhang X; Luk A; Jiang W; Liu S; Zhang Q
    Cancer Chemother Pharmacol; 2021 Mar; 87(3):349-359. PubMed ID: 33169186
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men.
    Markus R; Chow V; Pan Z; Hanes V
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):755-763. PubMed ID: 28864922
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial.
    Suh CH; Yoo DH; Berrocal Kasay A; Chalouhi El-Khouri E; Cons Molina FF; Shesternya P; Miranda P; Medina-Rodriguez FG; Wiland P; Jeka S; Chavez-Corrales J; Linde T; Hrycaj P; Abello-Banfi M; Hospodarskyy I; Jaworski J; Piotrowski M; Brzosko M; Krogulec M; Shevchuk S; Calvo A; Andersone D; Park W; Shim SC; Lee SJ; Lee SY
    BioDrugs; 2019 Feb; 33(1):79-91. PubMed ID: 30719632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative assessment of clinical response in patients with rheumatoid arthritis between PF-05280586, a proposed rituximab biosimilar, and rituximab.
    Williams JH; Hutmacher MM; Zierhut ML; Becker JC; Gumbiner B; Spencer-Green G; Melia LA; Liao KH; Suster M; Yin D; Li R; Meng X
    Br J Clin Pharmacol; 2016 Dec; 82(6):1568-1579. PubMed ID: 27530379
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501.
    Markus R; McBride HJ; Ramchandani M; Chow V; Liu J; Mytych D; Fanjiang G
    Adv Ther; 2019 Aug; 36(8):1833-1850. PubMed ID: 31183781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects.
    Hillson J; Mant T; Rosano M; Huntenburg C; Alai-Safar M; Darne S; Palmer D; Pavlova BG; Doralt J; Reeve R; Goel N; Weilert D; Rhyne PW; Chance K; Caminis J; Roach J; Ganguly T
    Pharmacol Res Perspect; 2018 Feb; 6(1):. PubMed ID: 29417761
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers.
    Shin D; Lee YJ; Choi J; Lee D; Park M; Petkova M
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):567-575. PubMed ID: 32949267
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized, double-blind, parallel-group, single‑dose, pharmacokinetic bioequivalence study of INTP24 and bevacizumab in healthy adult men.
    Singh I; Patel R; Patel A; Jose V
    Cancer Chemother Pharmacol; 2020 Aug; 86(2):193-202. PubMed ID: 32627073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized, Double-Blind, Pharmacokinetic Equivalence Trial Comparing DRL-Rituximab With MabThera in Patients With Diffuse Large B-Cell Lymphoma.
    Viswabandya A; Shah S; Mukhopadhyay A; Nagarkar RV; Batra SS; Lopez-Lazaro L; Kankanwadi S; Srivastava A
    J Glob Oncol; 2019 Nov; 5():1-13. PubMed ID: 31809224
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension.
    Genovese MC; Glover J; Greenwald M; Porawska W; El Khouri EC; Dokoupilova E; Vargas JI; Stanislavchuk M; Kellner H; Baranova E; Matsunaga N; Alten R
    Arthritis Res Ther; 2019 Dec; 21(1):281. PubMed ID: 31831079
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A review of the totality of evidence in the development of ABP 798, a rituximab biosimilar.
    Cobb P; Niederwieser D; Cohen S; Hamm C; Burmester G; Seo N; Lehto SG; Hanes V
    Immunotherapy; 2022 Jun; 14(9):727-740. PubMed ID: 35543293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy.
    Choe JY; Prodanovic N; Niebrzydowski J; Staykov I; Dokoupilova E; Baranauskaite A; Yatsyshyn R; Mekic M; Porawska W; Ciferska H; Jedrychowicz-Rosiak K; Zielinska A; Choi J; Rho YH; Smolen JS
    Ann Rheum Dis; 2017 Jan; 76(1):58-64. PubMed ID: 26318384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis.
    Cohen S; Pablos JL; Pavelka K; Müller GA; Matsumoto A; Kivitz A; Wang H; Krishnan E
    Arthritis Res Ther; 2019 Mar; 21(1):84. PubMed ID: 30922373
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX04 to reference bevacizumab sourced from the United States, the European Union, and China in healthy Chinese male volunteers.
    Zhu X; Qian H; Sun J; Wu M; Yu C; Ding Y; Zhang X; Chai K; Li X
    Cancer Chemother Pharmacol; 2021 Sep; 88(3):465-474. PubMed ID: 34086067
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics, efficacy and safety of the rituximab biosimilar CT-P10.
    Coiffier B
    Expert Rev Clin Pharmacol; 2017 Sep; 10(9):923-933. PubMed ID: 28766389
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PF-06881894, a Proposed Biosimilar to Pegfilgrastim, Versus US-Licensed and EU-Approved Pegfilgrastim Reference Products (Neulasta
    Moosavi S; Borema T; Ewesuedo R; Harris S; Levy J; May TB; Summers M; Thomas JS; Zhang J; Yao HM
    Adv Ther; 2020 Jul; 37(7):3370-3391. PubMed ID: 32524499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A pharmacokinetics phase 1 bioequivalence study of the trastuzumab biosimilar MYL-1401O vs. EU-trastuzumab and US-trastuzumab.
    Waller CF; Vutikullird A; Lawrence TE; Shaw A; Liu MS; Baczkowski M; Sharma R; Barve A; Goyal P; Donnelly C; Sengupta N; Pennella EJ
    Br J Clin Pharmacol; 2018 Oct; 84(10):2336-2343. PubMed ID: 29926514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized phase l pharmacokinetic study comparing SB4 and etanercept reference product (Enbrel®) in healthy subjects.
    Lee YJ; Shin D; Kim Y; Kang J; Gauliard A; Fuhr R
    Br J Clin Pharmacol; 2016 Jul; 82(1):64-73. PubMed ID: 26972584
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial.
    Kim WS; Buske C; Ogura M; Jurczak W; Sancho JM; Zhavrid E; Kim JS; Hernández-Rivas JÁ; Prokharau A; Vasilica M; Nagarkar R; Osmanov D; Kwak LW; Lee SJ; Lee SY; Bae YJ; Coiffier B
    Lancet Haematol; 2017 Aug; 4(8):e362-e373. PubMed ID: 28712940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.